deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT01251874

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Breast Carcinoma Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Triple-Negative Breast Carcinoma
Interventions Biospecimen Collection Carboplatin Computed Tomography Fluorothymidine F-18 Positron Emission Tomography Veliparib
Updated 18 times since 2017 Last updated: Nov 20, 2025 Started: Nov 22, 2010 Primary completion: Sep 30, 2024 Completion: Nov 19, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Recurrent Breast Carcinoma and Stage IIIB Breast Cancer AJCC v7, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 18 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Nov 2017 · 5 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshot~Dec 2024 – ~Apr 2025 · 4 months · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Dec 2025 · 2 months · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

18 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Apr 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1

▶ Show 13 earlier versions

  1. Dec 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Completed → Active Not Recruiting

  3. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  6. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  7. May 2018 — Jun 2018 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  8. Mar 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE1

  9. Dec 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1

  11. Jun 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE1

  12. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1

  13. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations